Dupilumab‐associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report

• Main Authors: Marco Galluzzo (Author), Lorenzo Tofani (Author), Sara Spelta (Author), Marina Talamonti (Author), Alessandra Micera (Author), Luca Bianchi (Author), Marco Coassin (Author), Stefano Bonini (Author), Antonio Di Zazzo (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Dupilumab‐associated ocular surface disease is a common clinical sign appearing in patients with atopic dermatitis (AD) just few months after dupilumab treatment start, developing in about 25% of patients. Atopic keratoconjunctivitis (AKC) is a well‐identified clinical entity, defined as a...